| 1.47 -0.09 (-5.77%) | 10-12 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 2.1 |
1-year : | 2.45 |
| Resists | First : | 1.79 |
Second : | 2.1 |
| Pivot price | 1.42  |
|||
| Supports | First : | 1.38 |
Second : | 1.12 |
| MAs | MA(5) : | 1.5 |
MA(20) : | 1.38 |
| MA(100) : | 0.99 |
MA(250) : | 1.23 |
|
| MACD | MACD : | 0 |
Signal : | 0 |
| %K %D | K(14,3) : | 54.7 | D(3) : | 55 |
| RSI | RSI(14): 53.4 |
|||
| 52-week | High : | 2.54 | Low : | 0.56 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ CELU ] has closed below upper band by 42.3%. Bollinger Bands are 7% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 1.56 - 1.57 | 1.57 - 1.58 |
| Low: | 1.44 - 1.46 | 1.46 - 1.47 |
| Close: | 1.45 - 1.47 | 1.47 - 1.48 |
Celularity Inc. is a clinical-stage biotechnology enterprise dedicated to pioneering "off-the-shelf" allogeneic cell therapies, which are developed from placental sources. These innovative treatments are designed to combat a range of serious conditions, including various cancers, immune system dysfunctions, and infectious diseases. The company’s operations are segmented into three distinct areas: Cell Therapy, Degenerative Disease, and BioBanking. Their therapeutic pipeline features several key candidates: CYCART-19, a placental-derived CAR-T therapy, currently in Phase I trials for B-cell malignancies; CYNK-001, an unmodified natural killer (NK) cell also from placental sources, advancing through Phase I trials for acute myeloid leukemia and Phase I/IIa trials for glioblastoma multiforme and COVID-19; and CYNK-101, an allogeneic genetically modified NK cell, which is in Phase I for HER2+ gastric and gastroesophageal cancers. Furthermore, two mesenchymal-like adherent stromal cell candidates, APPL-001 and PDA-002 (both derived from placentas), are in pre-clinical development for Crohn's disease and facioscapulohumeral muscular dystrophy, respectively. In addition to its therapeutic development, Celularity is involved in commercial activities, offering surgical and wound care products like Biovance and Interfyl through sales and licensing agreements. The company also specializes in collecting stem cells from umbilical cords and placentas, providing storage services under its LifebankUSA brand. Founded in 2016, Celularity Inc. maintains its headquarters in Florham Park, New Jersey.
Wed, 07 Oct 2026
CELU Forecast — Price Target — Prediction for 2027 - TradingView
Wed, 30 Sep 2026
A Bali center is expected to be the region’s first to offer stem-cell treatment from placentas. - Stock Titan
Wed, 30 Sep 2026
Celularity Highlights Anticipated Quarter One 2027 Opening of Fontaine Vitale as Strategic Partner - Yahoo Finance
Tue, 29 Sep 2026
A profit, but not enough cash for the next 12 months: Celularity (NASDAQ: CELU) says it needs financing. - Stock Titan
Tue, 29 Sep 2026
Celularity Announces Naveen Jain to Join Board of Directors - Yahoo Finance
Tue, 29 Sep 2026
Celularity Inc 1Q 2026: Revenue $3.85M, EPS $0.02— 10-Q Summary - TradingView
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 32 (M) |
| Shares Float | 22 (M) |
| Held by Insiders | 33.1 (%) |
| Held by Institutions | 11.4 (%) |
| Shares Short | 391 (K) |
| Shares Short P.Month | 1,900 (K) |
| EPS | -2.74 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | -1.22 |
| Profit Margin | 0 % |
| Operating Margin | -263.5 % |
| Return on Assets (ttm) | -32.4 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | -66.4 % |
| Gross Profit (p.s.) | 0.03 |
| Sales Per Share | 0.58 |
| EBITDA (p.s.) | -1.67 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -9 (M) |
| Levered Free Cash Flow | -1 (M) |
| PE Ratio | -0.54 |
| PEG Ratio | 0 |
| Price to Book value | -1.22 |
| Price to Sales | 2.51 |
| Price to Cash Flow | -5.42 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|